Reversibility of androgen deprivation therapy in patients with prostate cancer

Journal of Urology

Volumn 173, Issue 3, 2005, Pages 784-789

  Fridmans, Alon ^a,b   Chertin, Boris ^a,b   Koulikov, Dmitry ^a,b   Lindenberg, Tzina ^a,b   Gelber, Hadassa ^a,b   Leiter, Chavie ^a,b   Farkas, Amicur ^a,b   Spitz, Irving M ^a,b  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Drug implants; Gonadorelin; Histrelin; Prostatic neoplasms; Testosterone

Indexed keywords

ANDROGEN; BICALUTAMIDE; FLUTAMIDE; GONADORELIN AGONIST; HISTRELIN; LUTEINIZING HORMONE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGED; CANCER STAGING; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; GLEASON SCORE; HUMAN; LOCAL ANESTHESIA; MALE; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 13744258397     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000152330.63175.a5     Document Type: Conference Paper

References (20)

1. Greenlee, R. T., Murray, T., Bolden, S. and Wingo, P. A.: Cancer statistics, 2000. CA Cancer J Clin, 50: 7, 2000
2. Huggins, C. and Hodges, C. V.: Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res, 1: 293, 1941
3. Treatment and survival of patients with cancer of the prostate. The Veterans Administration Co-operative Urological Research Group. Surg Gynecol Obstet, 124: 1011, 1967
4. Trachtenberg, J., Gittleman, M., Steidle, C., Barzell, W., Friedel, W., Pessis, D. et al: A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J Urol, 167: 1670, 2002
5. Conn, P. M., Janovick, J. A., Stanislaus, D., Kuphal, D. and Jennes, L.: Molecular and cellular bases of gonadotropin-releasing hormone action in the pituitary and central nervous system. Vitam Horm, 50: 151, 1995
6. Lahlou, N., Carel, J. C., Chaussain, J. L. and Roger, M.: Pharmacokinetics and pharmacodynamics of GnRH agonists: clinical implications in pediatrics. J Pediatr Endocrinol Metab, suppl., 13: 723, 2000
7. Oefelein, M. G.: Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration. J Urol, 160: 1685, 1998
8. Hall, M. C., Fritzsch, R. J., Sagalowsky, A. I., Ahrens, A., Petty, B. and Roehrborn, C. G.: Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer. Urology, 53: 898, 1999
9. Chertin, B., Spitz, I. M., Lindenberg, T., Algur, N., Zer, T., Kuzma, P. et al: An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer. J Urol, 163: 838, 2000
10. Sobin, L. H. and Fleming, I. D.: TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer, 80: 1803, 1997
11. Giberti, C., Barreca, T., Martorana, G., Truini, M., Franceschini, R., Rolandi, E. et al: Hormonal pattern and testicular histology in patients with prostatic cancer after long-term treatment with a gonadotropin-releasing hormone agonist analogue. Eur Urol, 15: 125, 1988
12. Hadžiselimović, F., Senn, E. and Bandhauer, K.: Effect of treatment with chronic gonadotropin releasing hormone agonist on human testis. J Urol, 138: 1048, 1987
13. Huhtaniemi, I., Nikula, H., Parvinen, M. and Rannikko, S.: Histological and functional changes of the testis tissue during GnRH agonist treatment of prostatic cancer. Am J Clin Oncol, suppl., 11: S11, 1988
14. Decensi, A. U., Guarneri, D., Marroni, P., Di Cristina, L., Paganuzzi, M. and Boccardo, F.: Evidence for testicular impairment after long-term treatment with a luteinizing hormone-releasing hormone agonist in elderly men. J Urol, 142: 1235, 1989
15. Shahidi, M., Norman, A. R., Gadd, J., Huddart, R. A., Horwich, A. and Dearnaley, D. P.: Recovery of serum testosterone, LH and FSH levels following neoadjuvant hormone cytoreduction and radical radiotherapy in localized prostate cancer. Clin Oncol, 13: 291, 2001
16. Spitz, I. M., Leiter, C., Chertin, B., Fridmans, A., Koulikov, D., Lindenberg, T. et al: GnRH superanalog implants for prostate cancer. In: Proceedings of the 12th International Congress of Endocrinology, Lisbon, Portugal. Bologna, Italy: Medimond Srl, pp. 389-395, 2004
17. Tyrrell, C. J., Kaisary, A. V., Iversen, P., Anderson, J. B., Baert, L., Tammela, T. et al: A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol, 33: 447, 1998
18. Grossfeld, G. D., Small, E. J., Lubeck, D. P., Latini, D., Broering, J. M. and Carroll, P. R.: Androgen deprivation therapy for patients with clinically localized (stages T1 to T3) prostate cancer and for patients with biochemical recurrence after radical prostatectomy. Urology, 58: 56, 2001
19. Dreicer, R.: The evolving role of hormone therapy in advanced prostate cancer. Cleve Clin J Med, 67: 720, 2000
20. Theyer, G. and Hamilton, G.: Current status of intermittent androgen suppression in the treatment of prostate cancer. Urology, 52: 353, 1998